Work

Impact of Statin Use on Outcomes in Triple Negative Breast Cancer

Year: 2017

Type: article

Abstract: Purpose: We sought to investigate if the use of HMG Co-A reductase inhibitors (statins) has an impact on outcomes among patients with triple negative breast cancer (TNBC).Methods: We reviewed the cases of women with invasive, non-metastatic TNBC, diagnosed 1997-2012.Clinical outcomes were compared based on statin use (defined as ever use during treatment vs. never use).We identified a subset of women for whom a 5-value lipid panel (5VLP) was available, including total cholesterol, low density lipoprotein, high density lipoprotein, very low density lipoprotein, and triglycerides.The Kaplan-Meier method was used to estimate median overall survival (OS), distant metastases-free survival (DMFS), and local-regional recurrence-free survival (LRRFS).A Cox proportional hazards regression model was used to test the statistical significance of prognostic factors.Results: 869 women were identified who met inclusion criteria, with a median follow-up time of 75.1 months (range 2.4-228.9months).293 (33.7%) patients used statins and 368 (42.3%) had a 5VLP.OS, DMFS, and LRRFS were not significant based on statin use or type.Controlling for the 5VLP values, on multivariable analysis, statin use was significantly associated with OS (HR 0.10, 95% CI 0.01-0.76),but not with DMFS (HR 0.14, 95% CI 0.01-1.40)nor LRRFS (HR 0.10 95% CI 0.00-3.51).Conclusions: Statin use among patients with TNBC is not associated with improved OS, although it may have a benefit for a subset of patients.Prospective assessment would be valuable to better assess the potential complex correlation between clinical outcome, lipid levels, and statin use.

Source: Journal of Cancer

DOI: 10.7150/jca.18743